Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways

Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways

Background Factor Xa (FXa) not only plays an active role in the coagulation cascade but also exerts non-hemostatic signaling through the protease-activated receptors (PARs). This study aimed to investigate whether the FXa inhibitor, Rivaroxaban (RIV), attenuates adverse cardiac remodeling in rats wi...

Full description

Bibliographic Details
Main Authors: Qian Zhang, Zhongfan Zhang, Weiwei Chen, Haikuo Zheng, Daoyuan Si, Wenqi Zhang
Format: Article
Language:English
Published: PeerJ Inc. 2023-09-01
Series:PeerJ
Subjects:
Rivaroxaban
Coagulation factor Xa
Adverse cardiac remodeling
Protease-activated receptors-2
Transforming growth factor β1 (TGFβ1)
Online Access:https://peerj.com/articles/16097.pdf

Internet

https://peerj.com/articles/16097.pdf

Similar Items